Cough Medicine and Drug Tests: Why Dextromethorphan Can Read as PCP

A donor takes an over the counter cough suppressant, shows up for a routine urine screen, and gets flagged for phencyclidine. It sounds unlikely, but it is one of the better documented false positive patterns in urine drug testing. The ingredient behind it is dextromethorphan, the DXM found in dozens of store brand and name brand cough and cold products. Understanding why it happens, and how a lab sorts out a real PCP result from a cough medicine artifact, helps donors and employers handle a non-negative screen correctly instead of jumping to conclusions.

What Cross Reactivity Means on an Immunoassay Screen

The initial urine cup or lab immunoassay test does not identify a specific molecule. It uses antibodies designed to bind to a target drug, and those antibodies sometimes bind to other compounds that share enough of the target's chemical shape. When that happens, the screen reads presumptive positive for a drug that was never actually taken. This is called cross reactivity, and it is a known limitation of every immunoassay platform, not a defect specific to any one brand of test.

Why Dextromethorphan Looks Like PCP to a Screening Antibody

A retrospective review of emergency department PCP screens published in the journal Clinical Toxicology looked at 491 positive results confirmed against actual patient histories. Dextromethorphan was present in 23.9 percent of screens that turned out to be false positives, compared with only 2.0 percent of screens that were confirmed as true PCP positives. The researchers attributed the overlap to structural similarity between the two compounds, both of which contain two six membered rings separated by a single carbon or nitrogen atom, a shape that some PCP antibodies do not distinguish cleanly from other molecules. The same review found tramadol and diphenhydramine associated with false positive PCP results as well, so dextromethorphan is not the only culprit, just the most frequently cited one. (PMC, Clinical Toxicology)

A separate toxicology review of common immunoassay pitfalls lists dextromethorphan, diphenhydramine, doxylamine, ibuprofen, imipramine, ketamine, meperidine, venlafaxine, bupropion, and tramadol as xenobiotics that have been reported to cause a false positive PCP screen. (PMC review, toxicology laboratory testing pitfalls)

Opiate Panel Cross Reactivity Is Also Possible

PCP is not the only panel where dextromethorphan can cause confusion. Chemically, dextromethorphan is a synthetic morphinan derivative related to levorphanol, and it has historically been described as a codeine analog even though it does not meaningfully activate opioid receptors the way true opiates do. Because of that structural kinship, occasional cross reactivity with opiate immunoassays has been reported in the clinical toxicology literature, generally at urine concentrations far above what a standard cough dose produces. It is a less common finding than the PCP overlap, but it is worth knowing about if a donor on high dose cough syrup shows an unexpected non-negative on an opiate panel as well. (NIH StatPearls, Dextromethorphan)

Typical Cough Medicine Doses vs What Triggers a Screen

Standard adult dosing for dextromethorphan is 10 to 20 mg every 4 hours or 30 mg every 6 to 8 hours, with a labeled ceiling of 120 mg in 24 hours for over the counter products. That is the range covered by a normal bottle of cough syrup or a package of lozenges used as directed. The dosing picture changes at recreational or misuse levels, sometimes called robotripping, where doses climb well above 4 mg per kilogram of body weight, a level associated with dissociative effects like euphoria and hallucinations in a majority of cases studied. (NIH StatPearls, Dextromethorphan) The emergency department review cited above did not require high dose or recreational use for dextromethorphan to correlate with a false positive PCP screen, which means ordinary therapeutic use of a cough product should not be dismissed as an unlikely explanation just because it was not an intentional misuse case.

Table compiled from a peer reviewed toxicology review of immunoassay false positives. (PMC review, toxicology laboratory testing pitfalls) Notably, ibuprofen appears on this list too, a reminder that PCP is far from the only panel where an ordinary OTC product can produce a false positive.

Which Drug Test Panels Include PCP

PCP has been part of the original federal drug testing panel since the framework was created, and federal agencies are authorized to test for it alongside marijuana, cocaine, opiates, and amphetamines under the mandatory guidelines that govern federal workplace testing. (SAMHSA, Federal Workplace Drug Testing FAQs) Outside of federal programs, PCP shows up on most panels sold to private employers, clinics, and treatment programs that go beyond the basic five drug screen, including common 6, 9, 10, 12, and larger multi panel cups. A program that only tests for marijuana, cocaine, and opiates on a narrow 3 or 5 drug panel may not include PCP at all, so the practical answer depends on which specific panel a given employer or clinic has chosen to buy. Employers building or restocking a testing program can review current panel options that include PCP to confirm exactly what a given cup screens for before assuming coverage.

How Confirmation Testing Separates DXM From Real PCP

A presumptive positive on an immunoassay cup or point of care device is never the final word. Federal drug testing regulations require that any non-negative initial result be sent to a certified laboratory for confirmation using gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry, methods that identify the exact molecule present rather than relying on antibody binding. (eCFR, Title 49 Part 40) Dextromethorphan and PCP have distinct molecular masses and fragmentation patterns, so confirmation testing reliably tells them apart even when the initial screen could not. A Medical Review Officer then reviews any confirmed result with the donor before it is reported to the employer, and this review is the point where a legitimate explanation, such as recent cough medicine use, gets documented. Our companion article walks through what lab confirmation does after a non-negative screen in more detail.

What Donors Should Disclose Before a Test

Donors are generally asked to list current medications, including over the counter products, at the time of collection or during the Medical Review Officer interview. Disclosing recent cough medicine use, even something as ordinary as a store brand DXM syrup, gives the reviewing physician the context needed to evaluate a non-negative PCP or opiate result properly. This is not a substitute for confirmation testing, and it does not guarantee a particular outcome, but it removes guesswork from the review process. A similar disclosure principle applies to other common OTC culprits, such as the well known overlap between pseudoephedrine and methamphetamine screening, where the same logic of disclose first, let confirmation testing do its job applies.

Employer Handling of a Non-Negative Screen

A non-negative immunoassay result is not a failed test. It is a signal that the specimen needs laboratory confirmation before any employment or program decision is made. Employers who act on a presumptive screen alone, without waiting for GC-MS or LC-MS/MS confirmation and Medical Review Officer review, risk making a decision based on an artifact rather than an actual finding. Programs that buy panels including PCP should have a written policy describing this two step process, so supervisors and HR staff are not tempted to treat a cup result as final.

Frequently asked questions

Can regular cough syrup use really cause a positive PCP drug test?

Yes. Dextromethorphan, the active ingredient in most over the counter cough suppressants, has been documented in clinical literature as one of the more frequent causes of a false positive PCP screen, and this has been observed with ordinary use, not only with high dose or recreational ingestion.

Does dextromethorphan show up as an opiate on a drug test too?

It can, though less often than the PCP overlap. Dextromethorphan is chemically a morphinan derivative related to codeine and levorphanol, and some opiate immunoassays have shown cross reactivity with it, typically at concentrations well above what a standard cough dose produces.

How does a lab tell dextromethorphan apart from actual PCP?

Confirmation testing with gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry identifies the exact molecule in the specimen rather than relying on antibody binding, which reliably distinguishes dextromethorphan from phencyclidine even when the initial screen could not.

What panels test for PCP?

PCP is part of the original federal five drug panel and is commonly included on 6, 9, 10, 12, and larger commercial multi panel drug tests. Narrow 3 or 5 drug panels built around marijuana, cocaine, and opiates only may not include it.

Should I tell the collector or Medical Review Officer that I took cough medicine?

Yes. Disclosing current over the counter and prescription medications at collection or during Medical Review Officer review gives the reviewing physician the information needed to evaluate a non-negative result accurately.

Related reading

• Prozac and Drug Tests: When Fluoxetine Triggers a False Positive
• EtG False Positives From Hand Sanitizer: What the Research Actually Shows
• Can Ibuprofen Cause a False Positive Drug Test?
• Nursing Student Drug Testing: What Clinical Placements Require

This article is general information about drug test screening chemistry and federal testing procedure, not medical advice. It is not a recommendation for or against using any medication, and it does not replace guidance from a physician, pharmacist, or Medical Review Officer regarding a specific test result.